JanOne is a biotechnology company dedicated to developing non-addictive treatments for diseases that cause severe pain, with a mission to reduce the reliance on opioid prescriptions. Their focus is on treating conditions at the source, starting with Peripheral Artery Disease (PAD), a condition affecting millions of Americans. JanOne aims to bring relief to those suffering from pain while minimizing the risk of addiction.
With their acquisition of JAN101, a promising treatment for PAD, JanOne is advancing towards Phase 2b trials expected to begin in late 2020. By addressing the underlying causes of pain and exploring non-addictive pain solutions, JanOne aims to make significant progress in the fight against opioid addiction and improve the lives of individuals affected by chronic and neuropathic pain.
Generated from the website